Key Takeaway: The phase 3 TIGeR-PaC study revealed that intra-arterial administration of gemcitabine (RenovoGem) significantly improves progression-free survival and overall survival in patients with locally advanced pancreatic cancer. In a study of 23 patients, RenovoGem showed a median progression-free survival of 15 months and an overall survival of 16 months, outperforming the standard treatment.
Price reaction · baseline $1.94 (2023-07-07 close) · hit pre-market · clean, no other RNXT news in the window
day 0 close · peak
+3.6%
Market Sentiment Analysis
POSITIVE FACTORS
Demonstrated prolonged progression-free survival with RenovoGem.
Median overall survival significantly higher than standard treatment.
Interim findings from a pivotal phase 3 study show promising results.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
12.3%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxel
Phase 3 · Locally Advanced Pancreatic Cancer
Full Press Release Details
Prolonged progression-free survival (PFS) has been demonstrated with intra-arterial (IA) administration of gemcitabine (RenovoGem) in patients with locally advanced pancreatic cancer (LAPC), according to interim findings from the pivotal phase 3 TIGeR-PaC study (NCT03257033). 1
Results presented during the 2023 European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer showed that in 23 patients, the median 8-month PFS was 15 months with RenovoGem compared with 7 months with the standard of care combination of gemcitabine plus nab-paclitaxel. In terms of overall survival (OS), the primary end point of the study, RenovoGem achieved a median OS of 16 months vs 10 months with gemcitabine/nab-paclitaxel. The OS results excluded roughly 5.5 months of life from the time of diagnosis to randomization during the induction chemotherapy and radiation phase of the study, according to a press release by RenovoRx.
View the entire article on Targeted Oncology
Frequently Asked Questions
What is RenovoGem used for?
RenovoGem is used for treating locally advanced pancreatic cancer.
What were the results of the TIGeR-PaC study?
The study showed a median progression-free survival of 15 months with RenovoGem.
How does RenovoGem compare to standard treatment?
RenovoGem achieved a median overall survival of 16 months, compared to 10 months for standard treatment.
What is the significance of the ESMO presentation?
The results were presented at the 2023 ESMO World Congress, highlighting the study's importance.